Chardan Capital Maintains Buy on Taysha Gene Therapies, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Geulah Livshits maintains a Buy rating on Taysha Gene Therapies (NASDAQ:TSHA) with a $7 price target.
August 13, 2024 | 9:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chardan Capital analyst Geulah Livshits maintains a Buy rating on Taysha Gene Therapies with a $7 price target.
The reaffirmation of a Buy rating and a $7 price target by Chardan Capital is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100